Hainan Huluwa Pharmaceutical Group Co., Ltd.
SSE:605199.SS
9.59 (CNY) • At close June 6, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1,413.548 | 1,795.184 | 1,515.046 | 1,353.793 | 1,161.706 | 1,305.918 | 983.773 | 655.005 | 487.354 |
| Cost of Revenue
| 737.106 | 907.792 | 638.582 | 545.097 | 443.654 | 496.786 | 379.954 | 336.976 | 291.208 |
| Gross Profit
| 676.443 | 887.391 | 876.464 | 808.696 | 718.052 | 809.132 | 603.819 | 318.029 | 196.146 |
| Gross Profit Ratio
| 0.479 | 0.494 | 0.579 | 0.597 | 0.618 | 0.62 | 0.614 | 0.486 | 0.402 |
| Reseach & Development Expenses
| 202.08 | 93.916 | 105.662 | 100.432 | 51.663 | 51.661 | 43.335 | 19.623 | 11.198 |
| General & Administrative Expenses
| 34.742 | 26.646 | 15.286 | 23.236 | 25.948 | 24.448 | 14.678 | 12 | 36.365 |
| Selling & Marketing Expenses
| 483.171 | 637.923 | 584.271 | 545.583 | 475.296 | 549.655 | 388.028 | 145.956 | 91.015 |
| SG&A
| 517.914 | 756.426 | 599.557 | 568.819 | 501.244 | 574.103 | 402.706 | 157.956 | 127.38 |
| Other Expenses
| 223.831 | 10.11 | 47.781 | 53.883 | 11.207 | 24.985 | 1.902 | 1.218 | 5.684 |
| Operating Expenses
| 943.825 | 868.412 | 753 | 723.135 | 564.114 | 650.749 | 477.698 | 269.007 | 144.194 |
| Operating Income
| -267.382 | 136.938 | 96.622 | 100.303 | 134.173 | 141.551 | 116.577 | 34.161 | 37.377 |
| Operating Income Ratio
| -0.189 | 0.076 | 0.064 | 0.074 | 0.115 | 0.108 | 0.118 | 0.052 | 0.077 |
| Total Other Income Expenses Net
| -1.784 | -1.444 | 0.605 | -18.64 | 0.216 | 0.691 | 1.902 | 1.218 | 5.684 |
| Income Before Tax
| -269.166 | 135.494 | 97.227 | 81.664 | 134.389 | 142.242 | 118.478 | 35.38 | 43.061 |
| Income Before Tax Ratio
| -0.19 | 0.075 | 0.064 | 0.06 | 0.116 | 0.109 | 0.12 | 0.054 | 0.088 |
| Income Tax Expense
| 0.351 | 22.873 | 12.485 | 12.108 | 12.887 | 21.912 | 17.939 | 13.252 | 9.298 |
| Net Income
| -274.457 | 106.498 | 85.682 | 72.138 | 121.502 | 120.329 | 100.539 | 22.128 | 33.763 |
| Net Income Ratio
| -0.194 | 0.059 | 0.057 | 0.053 | 0.105 | 0.092 | 0.102 | 0.034 | 0.069 |
| EPS
| -0.69 | 0.27 | 0.21 | 0.18 | 0.3 | 0.3 | 0.31 | 0.13 | 0.56 |
| EPS Diluted
| -0.69 | 0.27 | 0.21 | 0.18 | 0.3 | 0.3 | 0.31 | 0.13 | 0.56 |
| EBITDA
| -159.596 | 104.144 | 167.675 | 148.175 | 189.463 | 198.507 | 163.24 | 78.891 | 82.862 |
| EBITDA Ratio
| -0.113 | 0.058 | 0.111 | 0.109 | 0.163 | 0.152 | 0.166 | 0.12 | 0.17 |